Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Main Article Content

Richard Warren
Howard Sofen
Shinichi Imafuku
Jacek Szepietowski
Andrew Blauvelt
Lynda Spelman
Jessica Toms
Alex Buck
Subhashis Banerjee
Alan Menter

Keywords

deucravacitinib, plaque psoriasis, POETYK

Abstract

N/A

References

1. SOTYKTU™ (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

2. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

3. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

4. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

5. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021. Late breaker.

6. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021.

7. Warren RB, et al. Presented at the EADV Spring Symposium; May 12–14, 2022.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>